Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465621 · ClinicalTrials.gov registry record · Phase 2
Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00465621 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 150 participants.
The verdict
NCT00465621, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of thie study is to compare the safety and IOP-lowering efficacy of AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM to Xalatan dosed QD PM and Vehicle in patients with open-angle glaucoma or ocular hypertension
Interventions
- DRUG Xalatan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00465621
The ClinicalTrials.gov registry entry for NCT00465621 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xalatan is the first listed.
NCT00465621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00465621 about?
NCT00465621 is a clinical study titled "Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension". The purpose of thie study is to compare the safety and IOP-lowering efficacy of AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM to Xalatan dosed QD PM and Vehicle in patients with open-angle glaucoma or ocular hypertension
What is the current status of trial NCT00465621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2007-03.
What interventions are being tested in trial NCT00465621?
The interventions under investigation include: Xalatan (DRUG).
Who is sponsoring clinical trial NCT00465621?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.